December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.57 +1.45 (+6.84%)
Streaming Delayed Price Updated: 1:30 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
These biotechnology stocks are pushing ahead with promising innovations. 
Via The Motley Fool
News headline image
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
From Catalent, Inc.
Via Business Wire
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
2 Top Healthcare Stocks to Buy for the Long Haul ↗
These two companies are just getting started. 
Via The Motley Fool
News headline image
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
News headline image
Analyst Ratings for Sarepta Therapeutics ↗
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings: 
Via Benzinga
News headline image
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy ↗
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy. 
Via Investor's Business Daily
News headline image
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript ↗
SRPT earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
3 Unstoppable Stocks That Could Double in 5 Years ↗
The opportunities for these innovators are tremendous. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2022 ↗
These two drugmakers are growing in prominence. 
Via The Motley Fool
News headline image
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71% ↗
  Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading. 
Via Benzinga
News headline image
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
News headline image
Analyst Ratings for Sarepta Therapeutics ↗
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings: 
Via Benzinga
News headline image
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 2, 2022 ↗
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
7 Analysts Have This to Say About Sarepta Therapeutics ↗
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: 
Via Benzinga
News headline image
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications ↗
 
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
A Trio of Q3 Winners With Room to Run
It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside. 
Via MarketBeat
Topics Economy Stocks
News headline image
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst ↗
 
Via Benzinga
News headline image
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts ↗
 
Via Benzinga
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16% ↗
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating. 
Via Benzinga
News headline image
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
News headline image
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play ↗
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and... 
Via Benzinga
News headline image
Sarepta Therapeutics: Q2 Earnings Insights ↗
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sarepta Therapeutics... 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Sarepta Therapeutics Earnings Preview ↗
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta... 
Via Benzinga
News headline image
Earnings Scheduled For August 2, 2022 ↗
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.